Amneal Pharmaceuticals' Q4 performance exceeds expectations, but full-year guidance falls short of expectations

New Jersey Bridgewater - On Friday, Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported Q4 earnings that exceeded analyst expectations, but issued FY2026 guidance below Wall Street estimates.

The company’s stock was flat in pre-market trading following the announcement.

For the fourth quarter, the company reported adjusted earnings per share of $0.21, beating the consensus estimate of $0.18 by $0.03. Revenue reached $814.32 million, up 11% year-over-year from $731 million last year, surpassing analyst expectations of $806.02 million. However, the FY2026 guidance was disappointing, with projected revenue of $3.05 billion to $3.15 billion, below the market consensus of $3.21 billion.

The midpoint of $3.1 billion is about 3% lower than analyst estimates.

For FY2026, Amneal expects adjusted EPS of $0.93 to $1.03, with a midpoint of $0.98, slightly above the consensus estimate of $0.94. The company also projects adjusted EBITDA of $720 million to $760 million, up from $688 million in 2025.

“We are very pleased with Amneal’s sixth consecutive year of steady execution and strong growth,” said Co-CEOs Chirag and Chintu Patel. “Our full-year 2025 performance highlights the resilience of our diversified portfolio and the success of our strategic execution.”

Adjusted EBITDA for Q4 increased 13%, from $155 million in the same period last year to $175 million. Driven by CREXONT and UNITHROID, the specialty medicines segment revenue surged 38%, while AvKARE revenue jumped 24%. Due to timing of key product launches, generic drug revenue declined 1%.

For the full year 2025, Amneal reported revenue of $3.02 billion, up 8% year-over-year, with adjusted EPS of $0.83, compared to $0.58 in 2024.

This translation was assisted by artificial intelligence. For more information, please see our Terms of Use.